SecurityBPTH / Bio-Path Holdings, Inc. (09057N102)
President, CEO & CFONielsen Peter Henry
IndustryPharmaceutical Preparations
Institutional Owners9
Institutional Shares4,963,128 - 43.76%
Common Stock Shares Outstanding11,341,000 shares (as of 2018-03-31)
Institutional Value$ 6,439,000 USD

Institutional Stock Ownership and Shareholders()

BPTH / Bio-Path Holdings, Inc. Institutional Ownership

Bio-Path Holdings, Inc. (NASDAQ:BPTH) has 9 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4,963,128 shares. Largest shareholders include BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., University Of Texas Investment Managment Co, Commonwealth Equity Services, Inc, BlackRock Investment Management, LLC, WFG Advisors, LP, Sabby Management, LLC, BlackRock Advisors LLC, and Bank of New York Mellon Corp.
Bio-Path Holdings, Inc. (NASDAQ:BPTH) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/bpth"><img src="https://images.fintel.io/us-bpth-so.png" alt="BPTH / Bio-Path Holdings, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-02-10 13F-HR BlackRock Investment Management, LLC 308,832 313,763 1.60 432 424 -1.85
2017-02-10 13F-HR BlackRock Advisors LLC 48,011 49,387 2.87 67 67 0.00
2018-05-14 13F-HR Renaissance Technologies LLC 683,900 0 -100.00 138 0 -100.00
2018-05-15 13F-HR HighTower Advisors, LLC 60,000 0 -100.00 12 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 1,906,479 0 -100.00 386 0 -100.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 11,273 0 -100.00 2 0 -100.00
2018-05-14 13F-HR Virtu Financial LLC 30,016 0 -100.00 6 0 -100.00
2018-05-15 13F-HR UBS Group AG 38,554 0 -100.00 8 0 -100.00
2018-05-14 13F-HR Commonwealth Equity Services, Llc. 461,388 0 -100.00 93 0 -100.00
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 35,036 0 -100.00 7 0 -100.00
2018-05-07 13F-HR Crewe Advisors Llc 1,500 0 -100.00 0 0
2018-04-16 13F-HR Raymond James Financial Services Advisors, Inc. 149,276 0 -100.00 30 0 -100.00
2017-08-18 13F-HR WFG Advisors, LP 205,136 205,136 0.00 170 80 -52.94
2018-04-18 13F-HR Creative Planning 50,000 0 -100.00 10 0 -100.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 223 0 -100.00 0 0
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 9,300 0 -100.00 2 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 698,612 698,612 0.00 978 943 -3.58
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 524,570 0 -100.00 106 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 13,500 0 -100.00 3 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 2,455,293 2,837,783 15.58 3,437 3,831 11.46
2018-05-10 13F-HR JP Morgan Chase & Co 1,738 0 -100.00 0 0
2018-05-15 13F-HR/A Sabby Management, LLC 1,833,449 85,013 -95.36 371 170 -54.18
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 381,398 379,398 -0.52 148 137 -7.43
2018-05-15 13F-HR Frigate Ventures LP 1,342,099 0 -100.00 272 0 -100.00
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 6,592 0 -100.00 1 0 -100.00
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 20 0 -100.00 4 0 -100.00
2018-05-09 13F-HR NORTHERN TRUST CORP 123,872 0 -100.00 25 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 79,383 0 -100.00 16 0 -100.00
2018-04-30 13F-HR Ironwood Investment Counsel, LLC 44,674 0 -100.00 9 0 -100.00
2018-05-15 13F-HR Bank of New York Mellon Corp 123,400 10,948 -91.13 25 21 -16.00
2018-05-11 13F-HR UNIVERSITY OF TEXAS INVESTMENT MANAGMENT CO 3,830,882 383,088 -90.00 766 766 0.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 205,136 0 -100.00 42 0 -100.00
2018-05-09 13F-HR BBR PARTNERS, LLC 15,178 0 -100.00 3 0 -100.00
2018-05-14 13F-HR Hudson Bay Capital Management LP 774,084 0 -100.00 157 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 115,900 0 -100.00 23 0 -100.00
2018-05-15 13F-HR STATE STREET CORP 46,400 0 -100.00 10 0 -100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 838 0 -100.00 0 0
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 558,456 0 -100.00 113 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 1,151 0 -100.00 0 0

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q1 2018 Results - Earnings Call Transcript

2018-05-16 seekingalpha
Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. (39-0)

Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus

2018-04-06 zacks
It was a happening week for pharma stocks, Key developments this week included a new CAR-T deal for Pfizer (PFE - Free Report) , successful study results from Pfizer, Lilly (LLY - Free Report) and Allergan (AGN - Free Report) and positive regulatory updates from AstraZeneca (AZN - Free Report) . (161-0)

Bio-Path Leukemia Combo Study Shows Positive Early Data

2018-04-04 zacks
Bio-Path Holdings, Inc. announced positive interim data from phase II study (BP1001-201) on its lead pipeline candidate — prexigebersen — in combination with low-dose cytarabine (“LDAC”) for the treatment of patients with acute myeloid leukemia (“AML”) who cannot or choose not to be treated with more intensive chemotherapy. (58-1)

Your Daily Pharma Scoop: Geron Update, Rigel Setback, Bio-Path Results

2018-04-04 seekingalpha
Bio-Path announced positive preliminary results from mid-stage study of prexigebersen (BP1001) and low-dose cytarabine in AML. (312-1)

Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today

2018-04-03 investorplace
Bio-Path Holdings Inc (NASDAQ:BPTH) stock was up Tuesday on a few bits of good news from the company. (39-0)

CUSIP: 09057N102